Humana Inc. (HUM): Price and Financial Metrics
Humana Inc. (HUM)
Today's Latest Price: $443.15 USD
Updated Oct 22 2:31pm
Add HUM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 9 in Medical - Health Insurance
See all "A" rated Strong Buy stocks
HUM Stock Summary
- With a market capitalization of $57,842,278,632, Humana Inc has a greater market value than 96.61% of US stocks.
- The capital turnover (annual revenue relative to shareholder's equity) for HUM is 4.89 -- better than 91.12% of US stocks.
- Humana Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.9% of US equities in our set.
- Stocks that are quantitatively similar to HUM, based on their financial statements, market capitalization, and price volatility, are SHW, DG, PGR, ITW, and TJX.
- Visit HUM's SEC page to see the company's official filings. To visit the company's web site, go to www.humana.com.
HUM Stock Price Chart Interactive Chart >
HUM Price/Volume Stats
| Current price | $443.15 | 52-week high | $445.20 |
| Prev. close | $437.23 | 52-week low | $208.25 |
| Day low | $434.72 | Volume | 194,287 |
| Day high | $443.70 | Avg. volume | 1,048,337 |
| 50-day MA | $413.65 | Dividend yield | 0.57% |
| 200-day MA | $376.21 | Market Cap | 58.63B |
Humana Inc. (HUM) Company Bio
Humana operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The company was founded in 1964 and is based in Louisville, Kentucky.
HUM Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $443.15 | $1583.01 | 263% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Humana Inc. To summarize, we found that Humana Inc ranked in the 72th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 264.5% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for HUM, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 19.81 -- which is good for besting 85.78% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- HUM's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.07% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 256% |
| 1% | 259% |
| 2% | 263% |
| 3% | 266% |
| 4% | 270% |
| 5% | 273% |
UHS, SKVI, CRHM, NVO, and ANTM can be thought of as valuation peers to HUM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...